Original citation:

Permanent WRAP URL:
http://wrap.warwick.ac.uk/81316

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:
"This is an author-produced electronic version of an article accepted for publication in the British Journal of Psychiatry. The definitive publisher-authenticated version is available online at http://bjp.rcpsych.org

A note on versions:
The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher’s version. Please see the ‘permanent WRAP URL’ above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk
Tim Kendall FRCPsych
Director, NCCMH Royal College of Psychiatrists; Medical Director, Sheffield Health and Social Care NHS Foundation Trust tim.kendall@shsc.nhs.uk

Craig J. Whittington PhD
Global Head of Methodology, Innovation and Quality at Doctor Evidence; Formerly, Associate Director for Clinical Effectiveness, NCCMH cwhittington@doctorevidence.com

Elizabeth Kuipers FBPsS
Emeritus Professor of Clinical Psychology Institute of Psychiatry Psychology and Neuroscience, King’s College London. Elizabeth.kuipers@kcl.ac.uk

Sonia Johnson FRCPsych
Professor of Social and Community Psychiatry, UCL; consultant psychiatrist, Camden and Islington NHS Foundation Trust. s.johnson@ucl.ac.uk

Max J. Birchwood FBPsS
Professor of youth mental health, Warwick Medical School, University of Warwick. M.J.Birchwood@warwick.ac.uk

Max Marshall FRCPsych
Medical Director, Lancashire Care NHS Foundation Trust and Professor of Psychiatry Manchester University max.marshall@manchester.ac.uk

Anthony P. Morrison FBPsS
Professor of clinical psychology, university of Manchester and Director, psychosis research unit, greater Manchester west mental health foundation trust tonymorrison@ntlworld.com

On behalf of the NICE guideline development group for CG178
NICE versus SIGN on psychosis and schizophrenia: same roots, similar guidelines different interpretations

Summary
A recent editorial claimed that the 2014 NICE guideline on psychosis and schizophrenia, unlike its equivalent 2013 SIGN guideline, is biased towards psychosocial treatments and against drug treatments. In this article we underline that the NICE and SIGN guidelines recommend similar interventions, but that the NICE guideline has more rigorous methodology. Our analysis suggests that the authors of the editorial appear to have succumbed to bias themselves.

Introduction
In May 2015, Mark Taylor, co-chair of the Scottish Intercollegiate Guidelines Network (SIGN) guideline on schizophrenia published in 2013 (referred to hereafter as ‘SIGN131’) (Scottish Intercollegiate Guidelines Network, 2013), wrote an editorial for this journal (co-authored by Udayanga Perera) claiming that the National Institute for Health and Care Excellence (NICE) guideline on Psychosis and Schizophrenia (National Institute for Health and Care Excellence, 2014) (referred to hereafter as ‘CG178’) was open to a critique of bias, while SIGN131 was unbiased and evidence-based. They claimed that CG178 showed positive bias to psychosocial interventions, in particular cognitive behavioural therapy for psychosis (CBTp) and arts therapies, and showed negative bias to drug treatment.

Given the status that evidence-based guidelines in mental health now have in psychiatric practice, it is important to understand how one set of evidence can lead two guideline developers to two seemingly divergent views. It is important, and not mentioned in Taylor and Perera’s editorial, that both SIGN131 and CG178 are updates of the 2009 NICE guideline on schizophrenia (referred to here as ‘CG82’ (National Institute for Clinical Excellence, 2009). We will describe the institutions, processes and methodologies used for developing the NICE and SIGN guidelines, and then examine the claims made by the co-chair of SIGN131 about CG178.

NICE guideline production and the National Collaborating Centres
NICE began providing evidence-based guidance for the NHS in England in 1999 and has rapidly become one of the most important innovation in health and social care. The clinical guidelines programme is run by the National Collaborating Centres (NCCs), including the National Collaborating Centre for Mental Health (NCCMH) which produced the very first NICE guideline (on schizophrenia) in 2002. The World Health Organisation (WHO) evaluated this as the world’s best evidence-based guideline on schizophrenia, compared with 25 other national guidelines (Gaebel, Weinmann, Sartorius et al, 2005). The NCCMH has updated the original NICE guideline on schizophrenia twice (2009 and 2014).

Methodology, quality assurance and conflicts of interest
Each NICE guideline takes just over 2 years to produce by a Guideline Development Group (GDG), consisting of about 15 experts recruited through public advert, including researchers, professionals,
service users and carers, supported by a technical team, including systematic reviewers, health economists, information scientists, project managers and research assistants. The GDG is an independent advisory committee that strictly follows NICE’s published methodology (CG178 used the 2012 version of the guidelines manual (National Institute for Health and Care Excellence, 2012))\(^1\). All processes and products are continuously monitored and quality assured by NICE’s own commissioning managers, editors and technical support unit, and subjected to several stages of validation (including being critiqued by extensive stakeholder and external expert consultation and evaluation).

NICE takes the issue of conflicts of interest very seriously because of the potential threat to the integrity and transparency of the guidelines, and has a well-defined process for recording any interests and dealing with conflicts. If there are conflicts of interest related to certain topics a GDG member would be asked to leave the GDG meeting for the period of time that the topic of interest was being discussed. If a GDG member discloses an interest that significantly conflicts with their role as a GDG member they would be asked to leave the GDG entirely. Declarations of interest are included in the final guideline, and are in the public domain during the consultation of the guideline.

Finally, and an important difference between NICE 2014 and SIGN 2013, is that a person cannot be appointed as a NICE guideline chair if they have a personal pecuniary conflict of interest. This appears not to be the case for SIGN 2013.

**NICE and SIGN on schizophrenia: different scopes and different methods**

For NICE CG178, the evidence reviews for pharmacological and psychological interventions was not updated since NICE’s view (based on literature surveillance and expert consultation, including psychopharmacology experts) was that there had been insufficient new evidence since the publication of CG82 in 2009. Instead, NICE asked the NCCMH to expand the areas within the guideline to include self-management, carer experience, carer interventions and peer support, and to update service level interventions such as early intervention and assertive community treatment, areas that did have new evidence that might change guideline recommendations. Most of the reviews undertaken were new reviews conducted by the NCCMH guided by the GDG. All processes and methods were subject to the usual, extensive quality assurance, expert review and stakeholder consultation. Furthermore, in addition to making available the full guideline and appendices, NICE publishes minutes of the GDG meetings and documents from both consultations (scope and draft recommendations)\(^2\). As far as we can tell, none of this detailed information underpinning guideline development is publically available for SIGN guidelines.

For SIGN131, the scope was extended to include psychosis with coexisting substance misuse and perinatal issues (for both of these areas, NICE has whole guidelines\(^3\)). SIGN131 was largely based on CG82 and undertook a narrative synthesis of RCTs and other studies published between 2008 and 2011. The additional syntheses were undertaken by SIGN reviewers in conjunction with their GDG. The guideline did not undertake any de novo meta-analyses or update meta-analyses from CG82. SIGN131 underwent consultation and peer review, but documents from this process are not made routinely available.

**NICE and SIGN: how are they different?**

\(^1\) In October 2014, there was a major revision of the manual, which unified methodologies across all NICE programmes: https://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20Overview.
\(^2\) https://www.nice.org.uk/guidance/cg178/documents
\(^3\) http://www.nice.org.uk/guidance/cg120; http://www.nice.org.uk/guidance/cg192
The NICE and SIGN guidelines have a number of similarities, for example recommending the use of antipsychotics (including clozapine), family intervention, early interventions, assertive community treatment and CBTp. However, there are also many differences, ones which Taylor and Perera bring to the fore. We will deal with these in turn.

**Psychosis and schizophrenia versus schizophrenia**

Taylor and Perera criticise CG178 for including the term psychosis in the title as potentially ambiguous. The title change from ‘schizophrenia’ to ‘psychosis and schizophrenia’ came about through consultation with service users and professional groups who expressed the view that the guideline should update early intervention in psychosis services, which include people with ‘early psychosis’. It therefore made sense that the title reflected the content. The recent Schizophrenia Commission (independent of NICE) recommended exercising ‘extreme caution in making a diagnosis of schizophrenia as it can generate stigma and unwarranted pessimism’ and suggest ‘the more general term “psychosis” is preferable, at least in the early stages’.

**Psychological versus pharmacological interventions**

Taylor and Perera also suggest that, on a simple count of recommendations on psychological and pharmacological interventions, they have discovered bias in the NICE guideline. They assert that SIGN131 is less biased because 60% of all its recommendations refer directly to drug treatments, whereas a mere 24% of recommendations in CG178 refer to drugs and most of those are in combination with psychosocial interventions. Given the very different scopes and total recommendations of the two guidelines, this assertion is meaningless. For the record, CG178 includes 110 recommendations of which 24 (22%) are about psychological treatment and 31 (28%) are about antipsychotic medication. Only four recommendations are about both psychological and antipsychotic treatment. Counting recommendations on drugs and on psychological treatments has no grounding in evidence. The suggestion that these percentages mean that CG178 is biased against drug treatments and in favour of CBTp is, in our view, unfounded.

**CBT as a panacea**

Taylor and Perera also imply that CBTp is presented as a panacea. Certainly CG178 recommends that everyone with psychosis or schizophrenia should be offered CBTp on the basis of the systematic review and meta-analysis from 2009. The suggestion that a more recent, less favourable review (Jauhar et al., 2014) would have altered this recommendation ignores the fact that there were another 4 reviews of CBTp published last year (Burns, Erickson, & Brenner, 2014; Turner, Gaag, Karyotaki, & Cuijpers, 2014; Mark van der Gaag, Valmaggia, & Smit, 2014; Velthorst et al., 2015), and 4 of the 5 (including (Jauhar et al., 2014)) concluded that there were significant benefits to CBTp compared with treatment as usual or active control comparators. Additionally, their cited review (Jauhar et al., 2014) did not include any consideration of effects at follow-up, had not pre-registered their protocol and has been criticised (Peters, 2014) for idiosyncratic inclusion criteria and drawing conclusions unjustified by the evidence.

**Supposed bias in trials of CBT**

Taylor and Perera also cite the importance of masking in studies of CBTp, with effect sizes being lower in blinded trials. Blinding is an acknowledged problem in psychological treatment trials, which have the disadvantage that patients will know if they receive the treatment or a comparator. Blind assessors will not know however, and more recent CBTp trials include these. These sources of potential bias are also accounted for in NICE processes. While double blind drug treatment trials have the apparent advantage that patients do not know if they receive the drug or its comparator,

---

4 https://www.rethink.org/about-us/the-schizophrenia-commission
because side effects such as weight gain or extrapyramidal effects are noticeable, both patients and assessors may be able to guess. These issues are rarely discussed in drug trials.

However, it is unfortunate that Taylor and Perera make no mention of another bias, predominantly associated with the drug industry, of selective publication of studies. NICE guidelines have played a leading role in reducing the impact of bias across the board, including selective publishing (T. Kendall, Glover, Taylor, & Pilling, 2011). The NICE recommendation that CBTp be offered is made on the basis that some people respond and others will not, but we are currently unable to identify who is likely to benefit at an individual level. This is also the case for antipsychotics.

Taylor and Perera further propose that CBTp may be associated with specific adverse effects; while this is a possibility, current evidence, including from the very trials they cite, have shown fewer deteriorations (Anthony P. Morrison et al., 2014) and significant improvements in internalised stigma (A.P. Morrison et al., 2012) relative to comparators. Finally, in Taylor and Perera’s conclusions, they assert that CG178 makes strong recommendations based on no evidence at all, for instance that the dose of CBT should be at least 16 planned sessions. This is untrue; justification is provided in the relevant section of the full guideline (see 9.4.9)5, and SIGN131 contains the same recommendation.

**CBT for at-risk mental states**

For CG178, a meta-analysis of drug and psychological treatment trials for people thought to be at risk of psychosis (at-risk mental states; ARMS) was conducted. SIGN131 did not examine treatments for ARMS. ARMS were originally evaluated in the NICE guideline on psychosis and schizophrenia in children and young people (CG155; published in January 2013) and it was recommended that CBT should be considered as there was evidence of benefit, while treatment with antipsychotics appeared to show no benefit. For adults, CG178 strengthened this recommendation to ‘offer CBT’ for people with ARMS. This change occurred on the basis of inclusion of an additional trial in the meta-analysis that was conducted by the GDG (Stafford, Jackson, Mayo-Wilson, Morrison, & Kendall, 2013). The conclusion that CBT could prevent transition to psychosis at 12 months in some people was also replicated by 2 independent meta-analyses (Hutton & Taylor, 2013; M. van der Gaag et al., 2013) published in the period between CG155 and CG178.

**CBT alone for first episode psychosis**

CG178 states that, in order to promote consistency with CG155, ‘[for people with first episode psychosis] the GDG saw the value in advising practitioners of the equivocal evidence regarding psychological interventions when compared with antipsychotic medication and recommended that if a person wished to try a psychological intervention alone, this could be trialled over the course of 1 month or less’. A Cochrane review examining the effectiveness of antipsychotics versus placebo or psychosocial interventions in early schizophrenia concluded that the data are too sparse to assess the outcomes (Bola, Kao, & Soydan, 2012). As Taylor and Perera observe, absence of evidence is not evidence of absence of an effect, and we have no evidence to suggest that medication must be the first-line intervention for people who retain decision-making capacity. The recommendation to allow choice underlines the commitment to shared decision making and collaborative care that is emphasised in the NICE service user experience guideline (National Institute for Clinical Excellence, 2011), and also reflects the inclusion of people with lived experience as core members of the GDG, which is a strength rather than a weakness, since guidelines that do not take account of the wider context (including human rights issues) could be harmful. Although the guideline group concluded that adding an additional delay of one month to the duration of untreated psychosis was highly unlikely to have a deleterious effect on long term outcomes, CG178 nevertheless recommends:

---

5 http://www.nice.org.uk/guidance/cg178/evidence
‘advise people who want to try psychological interventions alone that these are more effective when delivered in conjunction with antipsychotic medication’.

**Arts therapies**

NICE CG178 included recommendations from CG82, which were based on a systematic review of a range of different psychosocial interventions. Apart from CBT and family intervention no other psychosocial intervention except for arts therapies was recommended in 2009. There were sufficient trials to undertake a meta-analysis of arts therapies, including art therapy, music therapy and body-dance movement therapy. SIGN131 did not undertake any review of arts therapies and yet Taylor and Perera criticise CG178 for giving a tentative recommendation for arts therapies in the treatment of negative symptoms. CG178 recommends that arts therapies may be considered for negative symptoms because early data suggested that arts therapies had an effect where drug treatments appear not to for negative symptoms. Moreover, the effect size for arts therapies in targeting negative symptoms was slightly larger than for CBT. As the intervention with the largest effect size, the GDG was justified in recommending this as a possible treatment. In doing so the GDG also increased the treatment options available to people with psychosis and schizophrenia. Updating these recommendations was not in the scope of CG178, and the more recent Matisse trial, not considered in CG82 is unlikely to change the recommendations (T. Kendall, 2012).

**Antipsychotics**

CG178 included recommendations from CG82 for the use of antipsychotic medication, with some amendments for clarity and for consistency with CG155. These recommendations were based on several systematic reviews covering: a) initial treatment of people with first-episode or early schizophrenia, b) oral antipsychotic medication in the treatment of the acute episode, c) promoting recovery in people with schizophrenia that is in remission, d) promoting recovery in people with schizophrenia whose illness has not responded adequately to treatment, e) treatment with depot/long-acting injectable antipsychotic medication, f) side effects of antipsychotic medication, g) effectiveness of antipsychotic medication based on pragmatic clinical trials, and h) health economic evidence. Taylor and Perera make a number of factually inaccurate claims about these recommendations. First, they claim there was an absence of a relevant expert on the GDG, and this led to ‘non-specific and vague’ recommendations about antipsychotic pharmacotherapy. However, CG82, which developed these recommendations, included several experts in psychopharmacology. Second, they state the recommendations do not reflect the evidence that there are efficacy differences between antipsychotics. However, as can be seen in section 10.10 of the full guideline, the GDG considered this issue. The recommendations reflect their view that treatment with antipsychotics should be considered an explicit individual therapeutic trial, with a collaborative choice of antipsychotic made by service user and professional together. Third, they claim that recommendation 10.11.1.116, which recommends not using a loading dose, illustrates that the guideline has ‘overlooked that long-acting injectable paliperidone palmitate requires a loading dose’. However, this recommendation is in a section specific to use of oral antipsychotics. In the section on using long-acting antipsychotics, it is recommended that prescribers follow the BNF or SPC. Finally, they suggest that CG178 does not include recommendations for ‘treatment-resistant schizophrenia and negative symptoms’ when these are, in fact, contained in sections 10.5 and 9.3.8.1. In our view, these assertions are both careless and irresponsible.

**What could explain the differences between the NICE and SIGN guidelines?**

---

6 Numbering is based on the full version of CG178.
The differences between the two guidelines in scope, methodology and rigour explain most, but not all, of the differences between SIGN and NICE on psychosis and schizophrenia. NICE probably does undertake a more exacting and reliable approach and has covered much more ground in much greater depth in psychosis and schizophrenia than SIGN have to date (NICE have 5 guidelines of direct relevance). However, the differences between NICE (CG178) and Taylor and Perera’s views are much greater than between the content of NICE (CG178) and SIGN (SIGN131). It is important to restate that the NICE (CG178) and the SIGN (SIGN131) guidelines are both based upon the NICE guideline of 2009 - CG82 - a fact not even acknowledged in Taylor and Perera’s editorial. Indeed, their editorial uses the evidence, and guideline recommendations, selectively, and in so doing demonstrates surprisingly limited knowledge of both the 2009 (CG82) and the 2014 (CG178) NICE guidelines and the evidence upon which these guidelines have been developed. In misrepresenting CG178, Taylor and Perera may themselves be guilty of bias.

In our view, disagreement, analysis and debate are essential aspects of an intellectual culture rooted in evidence-based medicine, whereas ill-supported accusations of bias, and going beyond the evidence is not. This is why NICE has such rigorous methodologies and structures underpinning the production of their guidelines.


**Declarations of interest**

TK receives c.£1.2Million per year from NICE to develop NICE guidelines in mental health and chaired the original NICE guideline (2002). Since then, TK has facilitated 18 NICE guidelines, including the NICE guideline on schizophrenia (2009), psychosis and schizophrenia in children and young people (2013) and psychosis and schizophrenia in adults (2014). TK is now leading the introduction of Improving Access and Waiting Times (NICE implementation) programme for NHS England. TK has lead a NICE collaboration with the Netherlands, Turkey and Georgia to share or develop national guidelines programmes and declares he has an “allegiance bias” in favour of NICE but not against SIGN.

CW was the lead systematic reviewer for the NICE guidelines on schizophrenia (2002 and 2009) and on psychosis and schizophrenia (2014), as well as numerous other NICE guidelines.
EK chaired the NICE guidelines on schizophrenia (2009) and on psychosis and schizophrenia (2014). EK is a CBTp practitioner and has written many articles on CBTp.

SJ was a member of the guideline committee on psychosis and schizophrenia (2014).

MJB was a member of the NICE guideline on psychosis and schizophrenia in children (2013) and in adults (2014) and is a CBTp practitioner.

MM was a member of the NICE guidelines on schizophrenia (2002) and on psychosis and schizophrenia (2014).

APM was a member of the NICE guideline on psychosis and schizophrenia in children and young people (2013) and in adults (2014). APM is also a practitioner of cognitive therapy and delivers this intervention within the UK National Health Service. APM also receives royalties from texts or books published on cognitive therapy. APM has received fees for delivering workshops on cognitive therapy.